Mark R. Olsen

1.2k total citations
20 papers, 774 citations indexed

About

Mark R. Olsen is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Mark R. Olsen has authored 20 papers receiving a total of 774 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Mark R. Olsen's work include Lung Cancer Treatments and Mutations (8 papers), Renal cell carcinoma treatment (6 papers) and Lung Cancer Research Studies (5 papers). Mark R. Olsen is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Renal cell carcinoma treatment (6 papers) and Lung Cancer Research Studies (5 papers). Mark R. Olsen collaborates with scholars based in United States, Germany and New Zealand. Mark R. Olsen's co-authors include Philip Bonomi, Ramaswamy Govindan, Craig H. Reynolds, Susan C. Guba, Edward B. Garon, Jyoti D. Patel, Mark A. Socinski, David R. Spigel, Thomas E. Hutson and Robert C. Hermann and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Endocrinology.

In The Last Decade

Mark R. Olsen

19 papers receiving 762 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark R. Olsen United States	12	591	416	257	174	48	20	774
Ursula Vogl Austria	9	417 0.7×	397 1.0×	341 1.3×	171 1.0×	52 1.1×	20	878
Huamao Mark Lin United States	18	618 1.0×	582 1.4×	317 1.2×	166 1.0×	42 0.9×	73	1.0k
Kristina Lamberg Sweden	13	427 0.7×	414 1.0×	194 0.8×	139 0.8×	62 1.3×	20	789
Robin Wiltshire United States	11	721 1.2×	556 1.3×	290 1.1×	150 0.9×	36 0.8×	17	824
Sasja F. Mulder Netherlands	12	340 0.6×	253 0.6×	265 1.0×	130 0.7×	43 0.9×	38	669
Rossana Ruiz Peru	14	256 0.4×	391 0.9×	228 0.9×	134 0.8×	46 1.0×	47	718
Yoshiro Fujiwara Japan	16	592 1.0×	618 1.5×	220 0.9×	172 1.0×	43 0.9×	30	841
Lisa Cupit United States	9	647 1.1×	462 1.1×	404 1.6×	217 1.2×	28 0.6×	15	891
Davorin Radosavljević Serbia	14	570 1.0×	665 1.6×	194 0.8×	106 0.6×	72 1.5×	53	952
Sylvie Négrier France	15	578 1.0×	342 0.8×	481 1.9×	334 1.9×	72 1.5×	37	883

Countries citing papers authored by Mark R. Olsen

Since Specialization

Citations

This map shows the geographic impact of Mark R. Olsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark R. Olsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark R. Olsen more than expected).

Fields of papers citing papers by Mark R. Olsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark R. Olsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark R. Olsen. The network helps show where Mark R. Olsen may publish in the future.

Co-authorship network of co-authors of Mark R. Olsen

This figure shows the co-authorship network connecting the top 25 collaborators of Mark R. Olsen. A scholar is included among the top collaborators of Mark R. Olsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark R. Olsen. Mark R. Olsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Emamekhoo, Hamid, Mark R. Olsen, Bradley Curtis Carthon, et al.. (2021). Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial.. Journal of Clinical Oncology. 39(15_suppl). 4515–4515. 5 indexed citations

Emamekhoo, Hamid, Mark R. Olsen, Bradley Curtis Carthon, et al.. (2021). Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. Cancer. 128(5). 966–974. 31 indexed citations

McFarlane, Joshua J., Mark D. Kochenderfer, Mark R. Olsen, et al.. (2020). Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. Clinical Genitourinary Cancer. 18(6). 469–476.e4. 29 indexed citations

Emamekhoo, Hamid, Mark R. Olsen, Bradley Curtis Carthon, et al.. (2019). Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.. Journal of Clinical Oncology. 37(15_suppl). 4517–4517. 27 indexed citations

Spigel, David R., Jyoti D. Patel, Craig H. Reynolds, et al.. (2015). Quality of Life Analyses from the Randomized, Open-Label, Phase III PointBreak Study of Pemetrexed-Carboplatin-Bevacizumab followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 10(2). 353–359. 22 indexed citations

Reynolds, Craig H., Jyoti D. Patel, Edward B. Garon, et al.. (2014). Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 16(3). 200–208. 7 indexed citations

Bonomi, Philip, Joseph R. Mace, Romeo A. Mandanas, et al.. (2013). Randomized Phase II Study of Cetuximab and Bevacizumab in Combination with Two Regimens of Paclitaxel and Carboplatin in Chemonaive Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 8(3). 338–345. 14 indexed citations

Patel, Jyoti D., Edward B. Garon, Ramaswamy Govindan, et al.. (2013). Exploratory analyses of efficacy and safety of pemetrexed (Pem) plus bevacizumab (Bev) and bev alone as maintenance therapy (MT) in patients (Pts) with stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC).. Journal of Clinical Oncology. 31(15_suppl). 8012–8012. 4 indexed citations

Socinski, Mark A., Jyoti D. Patel, Edward B. Garon, et al.. (2013). A phase III study of pemetrexed (Pem) plus carboplatin (Cb) plus bevacizumab (Bev) followed by maintenance pem plus bev versus paclitaxel (Pac) plus cb plus bev followed by maintenance bev in stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC): Overall and age group results.. Journal of Clinical Oncology. 31(15_suppl). 8004–8004. 16 indexed citations

10.

Patel, Jyoti D., Mark A. Socinski, Edward B. Garon, et al.. (2013). PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 31(34). 4349–4357. 281 indexed citations

11.

Reynolds, Craig H., Jyoti D. Patel, Edward B. Garon, et al.. (2013). Randomized phase III trial of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (Bev) followed by maintenance Pem+Bev (Pem arm) versus paclitaxel (Pac)+Cb+Bev followed by maintenance Bev (Pac arm) in patients (pts) with stage IIIb/IV nonsquamous non-small cell lung cancer (nsNSCLC) (POINTBREAK): African American (AA) subset.. Journal of Clinical Oncology. 31(15_suppl). e19150–e19150. 2 indexed citations

12.

Spigel, David R., Jyoti D. Patel, Craig H. Reynolds, et al.. (2012). Patient-reported outcomes from POINTBREAK: The randomized, open-label, phase III study of pemetrexed (pem) + carboplatin (cb) + bevacizumab (bev) followed by maintenance pem + bev versus paclitaxel (pac) + cb + bev followed by maintenance bev in patients with stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC).. Journal of Clinical Oncology. 30(34_suppl). 53–53. 2 indexed citations

13.

Motzer, Robert J., Thomas E. Hutson, Mark R. Olsen, et al.. (2012). Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma. Journal of Clinical Oncology. 30(12). 1371–1377. 208 indexed citations

14.

Motzer, Robert J., Thomas E. Hutson, Mark R. Olsen, et al.. (2011). Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial.. Journal of Clinical Oncology. 29(7_suppl). LBA308–LBA308. 31 indexed citations

15.

Robins, H. Ian, Anne O’Neill, Mark R. Gilbert, et al.. (2007). Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial. Cancer Chemotherapy and Pharmacology. 62(2). 227–233. 46 indexed citations

16.

Robins, H. Ian, Kendra D. Tutsch, Elaine L. Jacobson, et al.. (1999). Phase I Trial of Intravenous Thymidine and Carboplatin in Patients With Advanced Cancer. Journal of Clinical Oncology. 17(9). 2922–2922. 5 indexed citations

17.

Nicholson, Brian K., et al.. (1999). Orthomanganation of the iminophosphorane Ph3PNPh, and of triphenylarsine-oxide and -sulfide. Journal of Organometallic Chemistry. 579(1-2). 243–251. 25 indexed citations

18.

Olsen, Mark R. & Richard R. Love. (1998). Hormonal strategies for the prevention of breast cancer. Cancer treatment and research. 94. 135–157.

19.

Olsen, Mark R., et al.. (1986). Characterization of Rabbit Uterine Estrogen Receptor Proteins by Radioiodination and Partial Peptide Mapping*. Endocrinology. 119(5). 2177–2185. 7 indexed citations

20.

Olsen, Mark R., et al.. (1984). An immobilized antiestrogen binds a specific uterine protein in addition to estrogen receptor proteins. Molecular and Cellular Endocrinology. 35(2-3). 143–149. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact